Abstract
Aims Pulmonary arterial hypertension (PAH) is a severe pulmonary vascular disease with high mortality rates. This research aimed to examine the disease burden of PAH including prevalence, incidence, mortality, and disability-adjusted life-years (DALYs) from 1990 to 2021 across various age groups, sexes, and Socio-demographic Index (SDI) levels, at global, regional and national levels.
Methods Data was collected from the Global Burden of Diseases, Injuries, and Risk Factors study (GBD) 2021, which established models to estimate the burden of PAH for 204 countries and territories from 1990 to 2021. Age-standardized rates for PAH prevalence, incidence, mortality, and DALYs were calculated. Joinpoint regression was used to assess temporal trends. The correlation between disease burden and socioeconomic development was analyzed.
Results In 2021, the global age-standardized prevalence and incidence rates were 2.28 and 0.52 per 100,000 population, respectively. From 1990 to 2021, the age-standardized mortality rate decreased from 0.35 to 0.27 per 100,000, with an average annual trend of -0.82%. The Corresponding Author Dr. Qian Wang, Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, No. 1, Shuaifuyuan, Wangfujing Ave, Dongcheng District, Beijing 100730, China E-Mail: wangqian_pumch{at}126.com age-standardized DALY rate decreased from 13.21 to 8.24 per 100,000 by -1.52%. Females exhibited a higher incidence rate but lower mortality and DALY rates. The burden of PAH distributed unequally, with regions possessing higher socioeconomic statuses exhibiting lower mortality and DALY rates. Such inequalities have been improved over past decades.
Conclusions The decline in mortality and DALY rates of PAH indicates improvements in disease management and patient outcomes, while the health inequalities among different regions and countries persist. Improving survival and life quality, and global health equality are crucial for future progress.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the Chinese National Key Technology R&D Program, Ministry of Science and Technology (2021YFC2501301-5); CAMS Innovation Fund for Medical Sciences (CIFMS) (2021-I2M-1-005, 2019-I2M-2-008); and National High Level Hospital Clinical Research Funding (2022-PUMCH-D-009).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available human data that were originally located at https://vizhub.healthdata.org/gbd-results/.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced are available online at https://vizhub.healthdata.org/gbd-results/.
